3 days popular7 days popular1 month popular3 months popular

New Asthma Treatment For Children: Activaero Reports Therapeutic Benefit And High Acceptance From Phase II Trial

Proof-of-concept study successfully completed in asthmatic children (age 3-11) Activaero GmbH, the therapeutic area specialist for respiratory diseases, today announced positive results from its phase II trial in children with mild to moderate asthma. The clinical study was conducted with Activaero’s drug-device combination consisting of budesonide in liquid formulation and the Company’s proprietary controlled inhalation [...]

Elacytarabine In Combination With Idarubicin Shows Promising Efficacy In Phase II Trial In Patients With Early Stage Acute Myeloid Leukaemia (AML)

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed and results were presented* by Dr David Rizzieri from Duke University Medical [...]

Clinical Trials Have Shown Anti-Tumor Activity With New Targeted Therapy For Advanced Prostate Cancer

Few available treatment options exist once prostate cancer has spread to other parts of the body and has failed to respond to therapies that involve blocking the male hormone androgen. Patients with advanced, hormone-refractory prostate cancer usually die from the disease after 12 to 18 months, so new therapies are desperately needed. At the 24th [...]

Strategy For Reversing Type 1 Diabetes Supported By Ongoing Clinical Trial

A phase I clinical trial has confirmed that use of a generic vaccine to raise levels of an immune system modulator can cause the death of autoimmune cells targeting the insulin-secreting cells of the pancreas and temporarily restore insulin secretion in human patients with type 1 diabetes. Results of the study – led by Denise [...]

Second-Line Defense Needed For Patients With NSCLC

In lung cancer, patients who benefit from drugs like erlotinib will inevitably develop drug resistance. This is heralded by cancer growth and increasing tumor-related symptoms. Now scientists are investigating a second line of defense by studying the use of the novel AKT inhibitor MK-2206 in combination with erlotinib for patients whose benefit from erlotinib has [...]